You can bet that Sanofi's ($SNY) top brass are celebrating this evening. The French drugmaker's Genzyme unit won the long-sought FDA approval for its new plant in Framingham, MA. That facility can
Genzyme flexed some market muscle Wednesday when it announced the European Medicines Agency's approval of a new U.S. facility for production of Fabrazyme. Perhaps most immediately affected by the...
The U.K.'s cost-effectiveness watchdog has officially snubbed the Sanofi ($SNY) prostate cancer treatment Jevtana. The National Institute for Health and Clinical Excellence won't recommend the drug
It's a one-two punch for Montreal's labor market. Johnson & Johnson ($JNJ) and Sanofi ($SNY) both said they would lay off workers in the area as part of ongoing cost-cutting efforts. J&J will
You know the proverb: A man is known by the company he keeps. Well, a company can be known by the company it keeps, too. At least that's the hypothesis behind Insider Monkey's look at hedge-fund
Big Pharma is getting bitten by its deals with Indian generics-makers. One recent example, of course, is Japan's Daiichi Sankyo, which last month felt tremors from Indian unit Ranbaxy as the latter
Sanofi ($SNY) subsidiary Shantha Biotech plans to relaunch the company's pentavalent Shan5 vaccine in 2013. The vaccine was removed from the World Health Organization's prequalification list...
In anticipation of increased demand for biopharmaceuticals, Eli Lilly ($LLY) is planning a 22,000-square-meter bioprocessing plant at its Cork County site. The Dunderrow, Kinsale, location is
The year 2013 still appears correct for Sanofi's ($SNY) relaunch of its Shantha Biotech unit's Shan5 pentavalent vaccine, sidelined in 2010 by the World Health Organization because of a white residue
It's official: Sanofi ($SNY) has discontinued its authorized generic version of the Lovenox blood thinner. Apparently, the company thinks it can make more money selling the branded med only, since